动物造模,人脐带间充质干细胞 z-bio 2022-12-06 279

　　Objective To investigate the safety and efficacy of human umbilical cord mesenchymal stem cells (HUC MSCs) in the treatment of lipopolysaccharide (LPS) - induced acute lung injury in mice.

　　Methods The safety of HUC MSCs was evaluated by tumorigenicity test, hemolysis test in vitro and acute toxicity test. C57BL/6 male mice aged 6~8 weeks were used as experimental objects to establish acute lung injury model by intranasal or intraperitoneal injection of LPS. HUC MSCs were given 6 h after modeling, and the treatment group was divided into tail vein injection group (5 × 107 cells/kg), atomization group (HUC MSCs conditioned medium). The pathological results of lung tissues of mice in each group were observed 96 hours after modeling, and the number and classification of inflammatory cells in BALF of mice were observed by Rexhlet Giemsa staining.

　　Results HUC MSCs had no tumorigenicity, hemolytic reaction and acute toxicity. Compared with the control group, the two modeling methods had a certain degree of lung injury. The McGuigan score of lung tissue pathological section showed that the lung injury caused by intraperitoneal injection of LPS was more serious than that in the nasal drip group. Compared with the model group, the degree of lung tissue injury in the treatment group was significantly reduced, and the therapeutic effect of the tail vein injection group was better than that of the atomization group, and the number of macrophages in BALF was significantly increased (P<0.001).

　　Conclusion LPS intraperitoneal injection induced acute lung injury in mice is superior to intranasal administration. The tail vein injection of human umbilical cord mesenchymal stem cells can effectively treat acute lung injury in mice, and nebulization of HUC MSCs conditioned medium can alleviate lung inflammation in mice.